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ABSTRACT
Glioblastoma multiforme (GBM) is the most common and deadliest primary 
brain tumor, driving patients to death within 15 months after diagnosis (short 
term survivors, ST), with the exception of a small fraction of patients (long term 
survivors, LT) surviving longer than 36 months. Here we present deep sequencing 
data showing that peritumoral (P) areas differ from healthy white matter, but 
share with their respective frankly tumoral (C) samples, a number of mRNAs and 
microRNAs representative of extracellular matrix remodeling, TGFβ and signaling, 
of the involvement of cell types different from tumor cells but contributing to tumor 
growth, such as microglia or reactive astrocytes. Moreover, we provide evidence 
about RNAs differentially expressed in ST vs LT samples, suggesting the contribution 
of TGF-β signaling in this distinction too. We also show that the edited form of miR-
376c-3p is reduced in C vs P samples and in ST tumors compared to LT ones. As a 
whole, our study provides new insights into the still puzzling distinction between ST 
and LT tumors, and sheds new light onto that “grey” zone represented by the area 
surrounding the tumor, which we show to be characterized by the expression of 
several molecules shared with the proper tumor mass.
INTRODUCTION
Glioblastoma multiforme (GBM; World Health 
Organization [WHO] grade IV) is the most common and 
most malignant primary tumor of the brain. Excessive 
proliferation, diffuse infiltration into surrounding brain 
tissue and suppression of antitumor immune surveillance 
contribute to the malignant phenotype of glioblastomas. 
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Despite multimodal aggressive treatment, the prognosis 
of GBM patients is poor and the median survival time 
after diagnosis is still in the range of just 12 months [1], 
or even shorter [2]. An interesting exception to this rule 
is a small fraction (less than 10%) of GBM patients, 
referred to as long-term survivors (LTS), who survive 
longer than 36 months. Several attempts have been made 
to unravel the molecular differences at the basis of such 
a clinically relevant issue, addressing either the genomic 
aspects [3] or the mutation or methylation state of specific 
genes [4, 5]. Some studies also performed genome-
wide gene expression analyses by using the microarray 
technology, resulting in the discovery of differentially 
expressed genes [6]. Nonetheless, we are still far from 
the comprehension of the reasons leading a glioblastoma 
patient to survive significantly longer than another one.
Targeted therapies have been introduced for GBM, 
based on information obtained from molecular studies of the 
tumor tissue [7]. Nevertheless, no clear survival benefit has 
been demonstrated, probably because tumor tissue represents 
the last step of tumorigenesis involving a number of 
alterations allowing tumor cells to survive. Since recurrence 
occurs in peritumoral tissue in about 95% of patients [8], 
getting a deeper insight into the biology of the peripheral 
areas immediately surrounding tumors is of great interest, 
as it may unveil molecular alterations representing the first 
signs of the future malignant evolution to glioblastoma. In 
this regard, only a few works have addressed the question 
of which molecular alterations affect the brain area 
surrounding the tumor [9, 10]. These works have indicated 
that peritumoral areas are diverse and composed of several 
different cellular components, such as microglia, reactive 
astrocytes, T lymphocytes, and others [11]; at the same 
time, they have started showing that the peritumoral areas 
are deeply interested by molecular and metabolic changes 
rendering them very different from normal brain and much 
closer to transformed cells, or at least necessary to sustain 
the growth of the frankly tumor cells.
In this study, we report a broad analysis of central 
tumor samples, from both long term survivors (LT) and short 
term ones (ST), integrated by the same analysis performed 
on peritumoral areas from the same patients. We provide data 
from gene expression (SAGE) analysis and from microRNA 
deep sequencing that, as a whole, allow not only to draw a 
novel comprehensive picture of LT vs ST tumors, but also to 
shed light into the critical, tumor-supporting peritumor areas.
RESULTS
Gene expression (SAGE) analysis of GBM 
centers and peritumor areas reveals RNA 
molecules differentially expressed in all tumor 
centers vs their own peritumorareas
We collected frankly tumoral areas (C) as well 
as peritumoral areas from 4 long term (LT: survival 
longer than 36 months) and 9 short term (ST: survival 
shorter than 36 months) patients diagnosed with primary 
glioblastoma (Table 1a). The peritumoral samples (P) were 
collected at an average distance of 2 cm from the border 
of the enhanced tumor, and did not show any evidence 
of tumor presence at macroscopic evaluation performed 
by the surgeon. We submitted total RNAs extracted 
from these samples to SAGE profiling, and, for each 
C and P sample in our SAGE dataset, we determined the 
GBM subtype by calculating the single sample Gene Set 
Enrichment Analysis [12] for each SAGE profile relative 
to the classified gene lists from Verhaak et al. [13]. 
Single-sample GSEA (ssGSEA), an extension of Gene 
Set Enrichment Analysis (GSEA), calculates separate 
enrichment scores for each pairing of a sample and gene 
set. Each ssGSEA enrichment score represents the degree 
to which the genes in a particular gene set are coordinately 
up- or down-regulated within a sample. C samples were 
largely heterogeneous, showing correlation with neural 
(5/13 samples), mesenchymal (4/13 samples), classical 
(2/13 samples), or proneural (2/13 samples) subtypes. In 
contrast, the majority (8/13) of samples from P regions 
showed the highest correlation with the neural subtype. 
No specific enrichment in any subtype was observed when 
comparing the ST with the LT samples (Table 1b).
In order to investigate which RNA molecules 
can distinguish frank tumor areas (Cs) from the 
corresponding P regions, we analyzed our SAGE data 
for differentially expressed molecules. Filtering these 
results for those RNAs whose differential expression was 
characterized by a FDR < 0.05, yielded the transcripts 
listed in Suppl. Tables 1a and 1b. Among RNAs 
overexpressed in tumor centers vs peritumoral areas, only 
four were shared by STCs and LTCs (compare Suppl. 
Table 1a and 1b), while other molecules were specific 
of either STCs or LTCs. For example, STCs exhibited, 
compared to STPs, the overexpression of several markers 
of the mesenchymal subtype of glioblastoma [13], such 
as COL1A1, COL1A2, COL5A1, IGFBP6, DCBLD2, 
many of which are also typically expressed by microglia 
or reactive astrocytes in glioblastoma microenvironment 
[10]. Conversely, RNAs overexpressed in LTCs vs LTPs 
showed an enrichment in markers of the neural subtype of 
glioblastoma, such as BASP1, CDC42, and SH3GL2 [13].
We then asked a slightly different question, that 
is which RNAs are differentially expressed in each 
C vs P pair, so that their expression can distinguish each 
C sample when compared to its own P area. To this aim, 
we employed a ReliefF algorithm [14] in conjunction with 
leave-one-out cross validation to compute the average 
(over all validation folds) merit of every RNA molecule 
for the binary classification problem. Figures 1 and 2 show 
the heatmaps drawn based on average merit ranking for 
LT and ST comparisons, respectively. Among the 50 top 
ranking RNAs, both over-and under-expressed molecules 
(C vs P) were found in almost equal proportions. 
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Table 1a: Characteristics of patients analyzed in this study. 
Patient Sex Age Survival (months)
Peritumoral 
infiltration
SAGE miRNome
Long term
LT1 M 34 60 Yes 10% X X
LT2 F 29 54 no X X
LT3 F 71 36 no X X
LT4 F 46 53 Yes 30% X
Short term
ST2 F 62 15 Yes 20% X X
ST4 M 73 6 no X X
ST5 F 70 13 no X
ST7 M 54 15 Yes 30% X X
ST8 M 51 30 Yes 30% X X
ST9 M 64 17 no X
ST10 F 66 16 Yes 5% X X
ST11 M 67 13 no X X
ST12 M 70 19 Yes 30% X X
Table 1b: Classification of C and P samples according to Verhaak et al. [13] from single sample 
gene set enrichment analysis of SAGE datasets.
C P
Long term
LT1 PN NL
LT2 NL MES
LT3 NL CL
LT4 CL NL
Short term
ST2 NL NL
ST4 PN NL
ST5 NL CL
ST7 MES MES
ST8 MES NL
ST9 NL NL
ST10 MES NL
ST11 MES NL
ST12 CL CL
All patients were diagnosed of primary glioblastoma. The degree of infiltration in the peritumor areas was calculated as in ref. 70. 
The last two columns indicate which samples underwent SAGE and miRNome analysis, respectively.
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Figure 1: SAGE-based analysis of transcripts differentially represented in each pair of LTC vs LTP samples. The 
heatmap shows the top 50 highest ranking RNA molecules, based on their “average merit”. The middle panel shows all 50 top RNA 
molecules, based on their average merit; in the left panel, only RNAs underexpressed in each LTC vs its own LTP are shown; in the right 
panel, only RNAs overexpressed in each LTC vs its own LTP are shown. The range of Log2 change is depicted in the vertical color bar on 
the right of each panel, and the corresponding numbers are written on top of each panel. The right side of each panel reports the ranking 
position of each RNA, whose name is illustrated on the left side of the panel.
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Figure 2: SAGE-based analysis of transcripts differentially represented in each pair of STC vs STP samples. The 
heatmap shows the top 50 highest ranking RNA molecules, based on their “average merit”. The middle panel shows all 50 top RNA 
molecules, based on their average merit; in the left panel, only RNAs underexpressed in each STC vs its own STP are shown; in the right 
panel, only RNAs overexpressed in each STC vs its own STP are shown. The range of Log2 change is depicted in the vertical color bar on 
the right of each panel, and the corresponding numbers are written on top of each panel. The right side of each panel reports the ranking 
position of each RNA, whose name is illustrated on the left side of the panel.
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Interestingly, almost no RNAs were shared by LT C/P and 
ST C/P comparisons, with the exception of one noncoding 
isoform of ELOVL fatty acid elongase 1, which was more 
expressed in both STPs and LTPs when compared to their 
own tumor centers; however, amongst the mRNAs found 
to be overexpressed in both LTCs and STCs with respect 
to their P regions, several RNAs were seen to be involved 
in the same processes, such as those encoding for two 
nuclear pore complex proteins, RANBP2 and RANBP9 
(overexpressed in LTCs and STCs) respectively, or 
UBE3C and UBR1, both members of the ubiquitin protein 
ligase E3 complex (overexpressed in STCs and LTCs) or 
TMX4 and PRDX2, involved in cell redox homeostasis 
(overexpressed in the majority of STCs and LTCs). 
Among RNAs differentially expressed in the ST group, 
but not in the LT one, we found the prolylendopeptidase 
(PREP), highly expressed in each STC compared to its 
own STP. The enzyme encoded by this gene is a serine 
protease working at the digestion of ECM by fibroblasts 
upon fibroblast activation, in all those processes mediated 
by cancer associated fibroblasts and supporting tumor 
development [15], such as tissue remodeling, angiogenesis 
[16], and immune tolerance [17]. Another interesting 
example is ARHGAP29, encoding for Rho-GTPAse 
Activating Protein 29 (overexpressed in STCs vs STPs but 
not in LTCs vs LTPs): this mRNA is part of a previously 
described “mesenchymal” signature of glioblastoma [13], 
also found to be expressed by reactive astrocytes and 
microglia [10]. On the LT side, we found a consistent 
overexpression of neuritin 1 (NRN1), a neurotrophin 
promoting neuronal migration [18] and induced by 
hypoxia [19] (in all LTCs vs their respective LTPs). Two 
mRNAs whose expression characterizes LTCs vs LTPs, 
LRFN3 (encoding for Leucine Rich repeat and Fibronectin 
type III domain containing 3) and NR2F6 (Nuclear 
Receptor subfamily 2 group F member 6), were previously 
included in the “classical” signature of glioblastoma [13].
Taken together, these findings indicate that GBM 
centers show a different expression profile compared to 
peritumor areas, and that the mRNAs whose expression 
is relevant to distinguish C samples from P samples are 
different when comparing ST with LT patients.
All C and P samples, from both ST and LT 
patients, show a shared perturbed expression of 
a number of genes in comparison with healthy 
white matter
Even if C and P samples are obviously differentiated 
by the expression of many genes, one of the most 
important issues we wanted to address was to decipher 
the molecular signature, if any, shared by C and P samples 
when compared to normal controls of healthy white matter. 
To this aim, we compared our SAGE data from GBM 
patients to the RNA expression profile obtained through 
the same method on a healthy white matter sample. 
We found a limited number of genes (i.e. 11, Table 2a, 
p value < 0.05) underexpressed in both Cs and Ps of ST 
and LT patients, among which CNP and ENPP2 (encoding 
for 2′, 3′-cyclic nucleotide 3′ phosphodiesterase and for 
ectonucleotidepyrophosphatase/phosphodiesterase 2, 
respectively), both oligodendrocyte progenitor cell markers 
[20], and EDIL3, expressed by oligodendrocytes [20] and 
a marker of the “neural” subgroup of glioblastoma [13]. 
The overexpressed RNA molecules were slightly more (i.e. 
21, Table 2b, p value < 0.05) than the underexpressed ones, 
and included microvascular, proliferation and survival 
markers of GBM, such as COL4A1 and TOP2A [21, 22], 
ECM molecules, as NID1 [23], markers of activated 
microglia, as CXCL14 [24], and RNAs characterizing 
the “classical” glioblastoma subtype, such as RGS12 and 
SOCS2 [13], also expressed in activated astrocytes [25], 
or even the “mesenchymal” subtype, such as TGFBI [13]. 
Notably, some of the overexpressed RNAs showed a 
comparable level of increase in both Cs and Ps compared 
to healthy white matter, likely indicating that some 
molecular events are taking place in the peritumor areas, 
which closely resemble those overtly occurring in frankly 
tumor regions. Several of these genes encode proteins 
playing their roles in the extracellular matrix (ECM), and/
or in the regulation of cell-cell or cell-substrate adhesion, 
as collagen IV, CXCL14, and TGFBI. This indicates that 
ECM remodeling is a key process taking place in our 
samples.
We validated, by real-time qPCR, the differential 
expression of 8 mRNAs and 2 lncRNAs in in both STCs 
and STPs compared to healthy white matter, notably 
extending our SAGE results also to some new samples that 
had not been submitted to deep sequencing (Suppl. Table 5 
and Suppl. Fig. 1). We then chose to validate by WB if 
the differential expression of some mRNAs was paralleled 
by a consistent modulation of the corresponding protein 
products too. In fact, we could confirm that LMTK3, 
encoding for Lemur Tyrosine Kinase 3 known to promote 
invasion in breast cancer [26], was widely overexpressed 
in both Cs and Ps of LT and ST patients (Figure 3). SOCS2 
expression increase was confirmed at the protein level in 
the majority of tumor centers, while its overexpression 
in the peripheral areas was variable and in general less 
marked than in the centers (Fig. 3). Among the proteins 
whose increase we could validate, the strongest result 
was that of TGFBI, that we confirmed as overexpressed 
in nearly all LT, ST, P and C samples we assayed (Fig. 3).
The differential expression of some key RNAs 
characterizes samples from short term and long 
term patients
A further key question that needs to be addressed 
in the comprehension of glioblastoma is the difference 
existing between the most frequent short survival patients 
(ST) and those that survive longer than 36 months after 
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diagnosis, called long term survivors (LT). We thus 
searched our SAGE data for RNAs differentially expressed 
in these two categories, either in the comparison between 
tumor centers, or between peripheral areas.We started by 
focusing on RNAs whose expression difference between 
categories was statistically significant (i. e. FDR < 0.05). 
As shown in Table 3, 8 RNAs were overexpressed in 
STCs vs LTC, and only one underexpressed molecule 
reached this high statistical significance in the comparison. 
These RNAs include some whose involvement in GBM 
is soundly documented, such as PDGFRA [13], and also 
others, previously described in other types of solid tumors, 
but never in glioblastoma. Among these, two homeobox 
genes, HOXC10 and HOXD10, and TMSB15A, encoding 
for thymosin-beta-15A, a tumor motility gene promoting 
metastases in prostate cancer [27], all overexpressed 
in STCs vs LTCs. A strong difference in expression 
(Log2FC STC vs LTC = 4.4) was found for the mRNA 
CA3, encoding for carbonic anhydrase III, known to play 
an anti-oxidant role by working as an oxygen radical 
scavenger [28], and whose expression correlates with poor 
survival in GBM [29]. BCAR3, on the contrary, encoding 
for the SH2-containing signal transducer Breast cancer 
anti-estrogen resistance 3 [30], was clearly underexpressed 
(Log2FC = -2.07) in STCs vs LTCs. We chose to validate 
the differential expression of 3 out of such 8 molecules, 
and we could confirm all of them (Suppl. Fig. 2). A few 
genes were differentially expressed (FDR < 0.05) also 
between STPs and LTPs (Table 3), among which lumican 
(LUM), a proteoglycan with an established role in the 
control of tumor progression [31] that was underexpressed 
in STPs vs LTPs (Log2FC = -3.25).
When we extended our view of transcripts 
differentiating ST from LT samples also with a FDR 
higher than 0.05, among the RNAs more expressed in 
STCs vs LTCs, we found again TGFBI (Log2FC STC vs 
LTC = 1.8, p = 0.034), in agreement with its higher 
expression in all GBM samples vs healthy controls 
and likely as a sign of the greater aggressiveness of 
STCs vs LTCs. We also observed the overexpression of 
two molecules, COL6A2 (Log2FC STC vs LTC = 2.99, 
p = 0.0077) and the cell surface receptor CD44 (Log2FC 
STC vs LTC = 2.65, p = 0.019), commonly expressed 
in mesenchymal tissues [32] and associated with ECM 
remodeling [33]. Among the relevant genes overexpressed 
in STCs vs LTCs, we also detected two key transcription 
factors, SOX4 and SOX11 (Log2FC STC vs LTC = 2.58, 
p = 0.000458, and 2.75, p = 0.00236, respectively), 
usually associated with neural stem cells [34]. In particular 
SOX4, a direct TGF-β target gene, was demonstrated to 
sustain tumorigenicity of glioma-initiating cells [35]. 
Interestingly, when we compared the peripheral areas of 
ST vs LT patients, we found the overexpression (Log2FC 
STP vs LTP = 1.6, p = 0.0178) of IGFBP5, encoding for 
insulin-like growth factor binding protein 5, previously 
shown to be expressed by activated astrocytes in 
retinoblastoma, where they cooperate with tumor cells to 
promote tumorigenesis [36].
Table 2a: List of 11 shared genes underexpressed in Cs and Ps, both LT and ST, vs healthy white 
matter. 
Underexpressed Log2FCSTC Log2FCSTP Log2FCLTC Log2FCLTP
ADARB2 RNA-specific adenosine deaminase B2 −4.110 −1.972 −4.043 −2.419
C1ORF133 chromosome 1 open reading frame 133 −2.786 −1.597 −3.521 −1.585
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 −2.460 −1.541 −2.458 −1.873
CNP 2′, 3′-cyclic nucleotide 3′ phosphodiesterase −3.876 −1.563 −4.801 −1.937
EDIL3 EGF-like repeats and discoidin I-like domains 3 −3.207 −1.158 −3.557 −1.602
ELOVL1
elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3, yeast)-like 1 −3.477 −1.227 −3.993 −1.640
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 −4.128 −2.056 −5.594 −1.920
ICOSLG inducible T-cell co-stimulator ligand −2.048 −1.567 −3.516 −1.834
PADI2 peptidyl arginine deiminase, type II −3.024 −1.471 −3.921 −1.937
RPL21P44 ribosomal protein L21 pseudogene 44 −1.521 −1.319 −1.875 −1.559
TTC32 tetratricopeptide repeat domain 32 −2.016 −1.581 −2.550 −1.799
The last four columns show the Log2FC of STC, STP, LTC and LTP, respectively, vs healthy white matter
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We then submitted our differentially expressed 
RNAs to a category enrichment analysis by using DAVID 
bioinformatics resources [37, 38], to understand if ST 
tumors are distinguished from LT ones by specific cellular 
components or molecular pathways. As shown in Table 4, 
when considering the RNAs overexpressed in STCs vs 
LTCs, the extracellular matrix is the cellular component 
clearly prevalent, whereas the categories highly enriched 
in RNAs underexpressed in STCs vs LTCs are those of 
“synapse”, “cell junction”, “cation channel complex”, 
and similar ones related to neuronal development and 
differentiation. Also the molecular pathways enriched 
in STCs or LTCs are clearly different (Table 5): genes 
overexpressed in STCs vs LTCs are enriched in KEGG 
pathways such as “cell cycle”, and, significantly, “TGF-
beta signaling pathway”. On the contrary, and in agreement 
with the cellular component analysis, genes underexpressed 
in STCs vs LTCs are enriched in pathways involving the 
function of several types of synapses, calcium signaling 
pathway, and also chemokine signaling pathway.
Altogether, these results indicate that ST tissues 
differ from LT ones, especially for the expression of 
markers of TGF-β pathway, of reactive astrocytes, 
extracellular matrix remodeling and tumor cell motility.
The miRNome profiling of GBM centers and 
peritumor areas reveals microRNA molecules 
differentially expressed in all tumor centers vs 
their own peritumor areas
In order to improve our molecular picture of 
glioblastoma tissues, we performed a microRNA deep 
Table 2b: List of the 21 shared genes overexpressed in Cs and Ps, both LT and ST, vs healthy white 
matter. 
Overexpressed Log2FC vs ctr
STC STP LTC LTP
ARC activity-regulated cytoskeleton-associated protein 4.157 3.192 4.827 4.016
COL4A1 collagen, type IV, alpha 1 5.249 4.473 4.932 4.812
COL4A2 collagen, type IV, alpha 2 4.948 3.949 5.033 4.814
CXCL14 chemokine (C-X-C motif) ligand 14 4.467 2.880 4.110 4.104
EPHA4 EPH receptor A4 4.964 3.601 5.385 4.114
IDUA iduronidase, alpha-L- 7.250 6.714 7.389 6.538
LMTK3 lemur tyrosine kinase 3 4.578 3.627 4.339 3.566
LOC100126784 hypothetical LOC100126784 3.687 2.720 3.282 2.817
LOC389831 hypothetical gene supported by AL713796 4.506 3.902 4.616 4.878
LPHN2 latrophilin 2 4.122 3.946 4.869 3.228
LRRC55 leucine rich repeat containing 55 2.891 2.839 2.780 3.005
LSM6 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 5.128 4.788 5.323 5.102
METTL7B methyltransferase like 7B 4.134 4.393 5.044 5.994
NID1 nidogen 1 3.646 2.987 3.540 2.685
PGM2L1 phosphoglucomutase 2-like 1 4.576 2.714 5.110 3.386
RGS12 regulator of G-protein signaling 12 4.506 3.871 4.941 4.695
SLCO2A1 solute carrier organic anion transporter family, member 2A1 5.916 5.189 5.598 5.205
SOCS2 suppressor of cytokine signaling 2 3.055 2.849 3.066 2.571
STAC2 SH3 and cysteine rich domain 2 6.034 3.353 5.606 3.102
TGFBI transforming growth factor, beta-induced, 68 kDa 5.086 3.488 3.709 3.705
TOP2A topoisomerase (DNA) II alpha 170 kDa 6.766 5.940 5.572 5.473
The last four columns show the Log2FC of STC, STP, LTC and LTP, respectively, vs healthy white matter
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sequencing analysis on a cohort of samples almost 
completely overlapping (3 out of 4 LT and 7 out of 
9 ST) with those already studied by SAGE. The data we 
obtained were initially employed to check whether the 
sole miRNome expression is able, per se, to separate our 
samples into clinically relevant classes. In fact, as shown 
in Figure 4a, total miRNA expression could correctly 
clusterize most of GBM C and P samples, and, as expected, 
placed the healthy white matter control at one edge of 
the cluster prevalently made by P samples, opposite to 
C tissues. We then asked the same question previously 
posed with the SAGE data, i.e. which microRNAs are 
differentially expressed in all C/P pairs. For this purpose 
we made a paired analysis comparing the expression level 
of each C and P sample in the 10 analyzed samples. The 
heatmap shown in Figure 4b represents the miRNAs with 
expression significantly different (FDR < 0.05) in this 
comparison. Among miRNAs overexpressed in C vs P 
samples, we found miR-21-3p, miR-196b-5p, miR-135b-
5p, miR-183-3p, known as “oncomiRs” in several tumors, 
including glioblastoma [39–42]. In addition, we found 
a few other overexpressed miRNAs, such as miR-1246, 
miR-1290, miR-7641, and miR-503-5p, whose role 
in cancer or in glioblastoma hasn’t been investigated 
yet. We also found a larger number of underexpressed 
miRNAs in C vs P samples, among which miR-219a 
and miR-338-3p and miR-338-5p, with an established 
role in oligodendrocyte maturation [43], miR-34b and 
miR-34c, widely recognized as tumor suppressor miRNAs 
in general and specifically in GBM [44], but also several 
others, whose role in cancer is not known. We further 
confirmed our findings by validating also by real time 
qPCR the expression of 5 microRNAs among those shown 
in Figure 4b, and of three other randomly chosen ones 
(Suppl. Fig. 3).
A common set of microRNAs distinguishes C and 
P samples from healthy white matter
As for the SAGE analysis, we were interested in the 
comparison of C and P samples vs the healthy control, in 
search of molecular signatures able to differentiate not 
only frankly tumoral regions, but also the peritumoral 
areas, and thus corroborating the involvement of such 
regions in tumor onset, growth and support. We selected 
those miRNAs with a Log2FC vs healthy control of at 
least 1.5 for overexpressed miRNAs, or with a Log2FC 
vs healthy control of at least −1.5 for the underexpressed 
ones. Among overexpressed miRNAs, listed in Table 6a, 
we report several known “oncomirs”, such as miR-10b, 
Figure 3: WB validation of three proteins whose mRNAs were overexpressed in C and P samples compared to healthy 
control. The upper panel shows LT samples, whereas the lower panel shows ST samples. Among ST samples, ST2, ST4, ST5, ST8 (on the 
left) are the same samples already analyzed by SAGE; ST1, ST3, ST6, ST7 are additional ST samples.
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miRNAs of the miR-17-92 cluster, miR-21, miR-148 
and others, largely described for their roles in cancer 
and in glioblastoma specifically [45–47], even if not 
described in the peritumoral areas. In addition, we found 
a set of miRNAs, among which miR-503-5p, not only 
overexpressed in C and P samples vs healthy white matter, 
but also in Cs vs Ps (see Figure 4b), suggesting a direct 
correlation of its expression with the presence of tumor 
cells. Moreover, the average expression of two miRNAs, 
miR-18a-5p and miR-503-5p, resulted higher in ST tumors 
as compared to LT ones (Log2FC STC vs LTC = 2.52, 
and 2.25, respectively), suggesting a correlation between 
their expression and tumor aggressiveness. In this class 
of microRNAs correlated with the glioblastoma state, we 
inserted also three miRNAs that, apart from distinguishing 
P and C samples from healthy controls, showed also a 
differential expression between those peripheral areas 
with a detectable tumor cell infiltration and the non-
infiltrated ones. These three miRNAs, miR-182-5p, 
miR-183-5p and miR-96-5p (Log2FC PNI vs PI = −3.96, 
−3.76, −3.79, respectively, with respective p-values of 
8.96 × 10−5, 1.7 × 10−4, 1.64 × 10−4), interestingly belong 
to the same genomic cluster located on chromosome 7, 
and own a recognized role as mediators of TGFβ signaling 
in glioblastoma [48]. In the comparisons with healthy 
controls too, as for the C/P comparisons, we found a larger 
number of underexpressed microRNAs in tumor samples 
(both P and C, LT and ST) compared to healthy control 
(Table 6c). Among these, several miRNAs previously 
described as downregulated in glioblastoma were present, 
such as miR-128, miR-124, miR-129 [49, 50], but also 
many others, not yet described in this context, were found. 
Moreover, only four miRNAs, miR-146b-3p, miR-483-3p, 
miR-184, and miR-187-3p, were overexpressed in non 
infiltrated peritumoral areas vs infiltrated ones (Log2FC 
PNI vs PI = 3.17, p = 1.84 × 10−4, 3.18, p = 1.81 × 10−4, 
3.66, p = 2.03 × 10−5, 3.83, p = 9.43 × 10−6, respectively).
In order to investigate which functions can be most 
likely affected by the modulated miRNAs, we performed 
a DIANA miRPath analysis [51], that identifies KEGG 
pathways involving the mRNAs predicted to be targeted 
by the modulated miRNAs. The highest ranking pathways 
predicted to be affected by either overexpressed or 
underexpressed miRNAs are listed in Table 6b and 6d, 
respectively: many pathways are expected to be 
influenced by both classes of miRNAs, while some others 
are preferentially related to one class. For example, 
overexpressed miRNAs are predicted to affect “Regulation 
of actin cytoskeleton” and “p53 signaling” pathways, 
clearly representing the morphological modifications 
typical of tumor cells, and the complex molecular 
interactions downstream of p53.
Table 3: Differentially expressed (FDR < 0.05) genes between short-term survivors and long-term 
survivors tumor centers (upper panel), or between short-term survivors and long-term survivors 
peritumor areas (lower panel).
STC vs LTC
NCBI Ref Seq logFC P Value FDR gene name
NM_005514 8, 459013 0, 000002 0, 003635 HLA-B
NM_017409 8, 069505 0, 000001 0, 001902 HOXC10
NM_002148 6, 016672 0, 000012 0, 010763 HOXD10
NR_002196 5, 114100 0, 000065 0, 026086 H19
NM_005181 4, 403243 0, 000003 0, 003707 CA3
NM_006206 4, 392766 0, 000148 0, 039570 PDGFRA
NM_021992 4, 074948 0, 000145 0, 039570 TMSB15A
NM_002196 3, 329623 0, 000018 0, 011555 INSM1
NM_003567 −2, 071359 0, 000231 0, 048284 BCAR3
STP vs LTP
NCBI Ref Seq logFC P Value FDR gene name
NM_005514 8, 295445 0, 000001 0, 001162 HLA-B
NM_030630 3, 089356 0, 000048 0, 017168 C17orf28
NM_002345 −3, 253966 0, 000045 0, 017158 LUM
NM_152679 −3, 369693 0, 000014 0, 006437 SLC10A4
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C samples show a reduced percentage of A to G 
editing of miR-376c-3p
The editing of RNA sequences by adenosine 
deaminases is an important mode of modulation of RNA 
function [52], and has been shown to affect microRNA 
sequences too, with several functional consequences, 
among which the change in targeted mRNAs [53]. We 
then studied our microRNA sequencing data in search of 
possible sequence isoforms that may originate from an 
A to G editing, and we found that miR-376c-3p, even if 
not differentially expressed in C vs P samples or in tumor 
samples vs healthy control, was less edited in C samples 
with respect to the P ones, that owned a fraction of edited 
variants comparable to that of the healthy white matter. 
Specifically, the edited forms harbored a G in place of an A 
at nucleotide 6 starting from the 5′ of the mature miRNA, 
thus affecting its “seed” sequence and potentially its target 
mRNAs. As shown in Figure 5, most P samples showed 
a relative amount of edited miR-376c-3p which was 
comparable to that of the healthy control sample, while 
the majority of C samples owned a reduced percentage of 
the edited forms in favor of the unedited ones.
In order to verify the significance of these 
observation, we performed a chi-squared test by 
considering two independent groups, one made by the 
C samples group and the other made by the P samples 
counterpart. For each group, we summed all the 
normalized counts of the edited variants of the miRNA 
376c-3p, separating them from the unedited ones. The 
Figure 4: A. MicroRNA expression can correctly clusterize GBM C and P samples. Consensus non-negative matrix 
factorization clustering of miRNA expression data distinguishes two clusters: one is prevalently made of P samples and includes the 
healthy control (SB), the other is enriched by C samples. B. A selected number of miRNAs can clearly distinguish each C sample from its 
own P region. Shown is the fold change heatmap of differentially expressed miRNAs in the paired comparison P/C cell types. Each box 
refers to a specific C/P cell type comparison, the color scale reflects the relative Log2(Fold Change) (green indicates over expression in C 
samples, red indicates underexpression).
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Table 4: GO Cellular Components (CC) categories enrichment for genes either overexpressed 
(A) or underexpressed (B) in STCs vs LTCs. 
A
Id category Name category Adjusted p value
Non corr 
p value
Fold 
enrichment # Genes
GO:0005576 extracellular region 2.85e-07 4.57e-10 2.52 48
GO:0044421 extracellular region part 2.85e-07 6.95e-10 3.32 33
GO:0005615 extracellular space 2.99e-06 1.10e-08 3.50 27
GO:0031012 extracellular matrix 2.91e-04 1.42e-06 4.19 16
GO:0005578 proteinaceous extracellular matrix 1.78e-02 1.09e-04 3.68 12
GO:0031941 filamentous actin 1.10e-01 8.08e-04 16.15 3
GO:0009897 external side of plasma membrane 1.79e-01 1.75e-03 4.06 7
GO:0031091 platelet alpha granule 1.79e-01 1.65e-03 7.89 4
GO:0000808 origin recognition complex 2.01e-01 2.45e-03 26.31 2
GO:0005664
nuclear origin of 
replication recognition 
complex
2.01e-01 2.45e-03 26.31 2
GO:0044433 cytoplasmic vesicle part 2.20e-01 2.95e-03 2.66 11
GO:0005796 Golgi lumen 2.67e-01 3.91e-03 6.23 4
GO:0031093 platelet alpha granule lumen 4.60e-01 7.29e-03 7.56 3
GO:0034774 secretory granule lumen 5.06e-01 8.66e-03 7.10 3
B
Id category Name category Adjusted p value
Non corr 
p value
Fold 
enrichment # Genes
GO:0045202 synapse 1.49e-11 1.13e-14 4.82 35
GO:0030054 cell junction 9.96e-09 1.52e-11 3.43 39
GO:0044456 synapse part 8.50e-07 1.94e-09 4.32 24
GO:0016020 membrane 2.72e-05 9.72e-08 1.34 165
GO:0043005 neuron projection 2.72e-05 1.03e-07 3.04 29
GO:0071944 cell periphery 3.51e-04 1.60e-06 1.50 104
GO:0097060 synaptic membrane 9.46e-04 5.04e-06 4.32 14
GO:0045211 postsynaptic membrane 9.49e-04 5.78e-06 4.58 13
GO:0005886 plasma membrane 1.02e-03 6.95e-06 1.48 100
( Continued)
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B
Id category Name category Adjusted p value
Non corr 
p value
Fold 
enrichment # Genes
GO:0032591 dendritic spine membrane 1.74e-03 1.32e-05 49.97 3
GO:0042995 cell projection 1.78e-03 1.57e-05 2.07 38
GO:0034702 ion channel complex 1.78e-03 1.62e-05 4.16 13
GO:0044425 membrane part 1.91e-03 1.89e-05 1.34 131
GO:0034703 cation channel complex 2.87e-03 3.06e-05 5.05 10
GO:0043025 neuronal cell body 1.06e-02 1.21e-04 3.24 14
GO:0031224 intrinsic to membrane 1.44e-02 1.75e-04 1.32 115
GO:0030425 dendrite 1.85e-02 2.45e-04 2.89 15
GO:0008021 synaptic vesicle 1.85e-02 2.53e-04 4.85 8
GO:0044297 cell body 2.32e-02 3.36e-04 2.93 14
GO:0031226 intrinsic to plasma membrane 3.53e-02 5.37e-04 1.76 37
GO:0005887 integral to plasma membrane 3.70e-02 5.91e-04 1.77 36
GO:0016021 integral to membrane 4.10e-02 6.87e-04 1.29 110
GO:0043204 perikaryon 4.23e-02 7.41e-04 6.94 5
GO:0032589 neuron projection membrane 4.61e-02 8.76e-04 9.19 4
GO:0008328 ionotropic glutamate receptor complex 4.61e-02 8.76e-04 9.19 4
GO:0012505 endomembrane system 5.89e-02 1.17e-03 1.58 46
GO:0070044
synaptobrevin 
2-SNAP-25-syntaxin-
1a complex
6.42e-02 1.32e-03 33.32 2
GO:0044448 cell cortex part 1.45e-01 3.08e-03 4.21 6
GO:0034704 calcium channel complex 1.47e-01 3.25e-03 6.50 4
GO:0034705 potassium channel complex 1.70e-01 4.01e-03 4.76 5
GO:0008076
voltage-gated 
potassium channel 
complex
1.70e-01 4.01e-03 4.76 5
GO:0031045 dense core granule 1.79e-01 4.48e-03 19.04 2
GO:0044459 plasma membrane part 1.79e-01 4.47e-03 1.47 47
GO:0014701
junctional 
sarcoplasmic reticulum 
membrane
2.64e-01 7.54e-03 14.81 2
GO:0016529 sarcoplasmic reticulum 2.64e-01 7.63e-03 5.13 4
( Continued)
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Table 5: KEGG categories enrichment for genes either overexpressed (A) or underexpressed 
(B) in STCs vs LTCs. 
A
Id category Name category Adjusted p value
Non corr 
p value Fold enrichment # Genes
hsa05219 Bladder cancer 4.12e-02 3.30e-04 11.88 4
hsa04115 p53 signaling pathway 4.12e-02 1.74e-04 9.39 5
hsa04110 Cell cycle 4.12e-02 4.15e-04 6.08 6
hsa05144 Malaria 7.75e-02 1.04e-03 8.81 4
hsa05134 Legionellosis 1.55e-01 2.70e-03 6.81 4
hsa05202
Transcriptional 
misregulation in 
cancer
1.55e-01 3.12e-03 4.12 6
hsa04630 Jak-STAT signaling pathway 3.31e-01 7.77e-03 4.02 5
hsa04512 ECM-receptor interaction 3.67e-01 9.85e-03 4.73 4
hsa05214 Glioma 4.19e-01 1.41e-02 5.90 3
hsa04621 NOD-like receptor signaling pathway 4.19e-01 1.41e-02 5.90 3
hsa05218 Melanoma 4.82e-01 1.78e-02 5.40 3
hsa04060 Cytokine-cytokine receptor interaction 6.17e-01 2.49e-02 2.64 6
hsa04610 Complement and coagulation cascades 6.54e-01 2.85e-02 4.51 3
hsa05132 Salmonella infection 6.83e-01 3.21e-02 4.31 3
hsa04350 TGF-beta signaling pathway 7.13e-01 3.59e-02 4.12 3
( Continued)
B
Id category Name category Adjusted p value
Non corr 
p value
Fold 
enrichment # Genes
GO:0000145 exocyst 2.64e-01 7.54e-03 14.81 2
GO:0030136 clathrin-coated vesicle 2.64e-01 6.89e-03 2.51 10
GO:0030672 synaptic vesicle membrane 2.64e-01 7.13e-03 5.23 4
GO:0031201 SNARE complex 2.80e-01 8.30e-03 7.14 3
GO:0030424 axon 3.04e-01 9.27e-03 2.41 10
The grey background highlights GOCCs with an adjusted p-value < 0.05. Adjusted p-value represents the Benjamini – corrected p-value
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B
Id category Name category Adjusted p value
Non corr 
p value Fold enrichment # Genes
hsa05032 Morphine addiction 1.15e-04 2.47e-07 7.30 11
hsa04020 Calcium signaling pathway 1.34e-04 5.77e-07 5.03 14
hsa04727 GABAergic synapse 2.30e-04 1.49e-06 6.92 10
hsa04723
Retrograde 
endocannabinoid 
signaling
3.33e-04 2.88e-06 6.44 10
hsa04970 Salivary secretion 9.57e-04 1.03e-05 6.36 9
hsa04724 Glutamatergic synapse 1.38e-03 1.79e-05 5.26 10
hsa04726 Serotonergic synapse 6.02e-03 1.03e-04 4.77 9
hsa05414 Dilated cardiomyopathy 6.02e-03 1.04e-04 5.42 8
hsa04080 Neuroactive ligand-receptor interaction 1.49e-02 2.89e-04 3.06 13
hsa04666
Fc gamma 
R-mediated 
phagocytosis
3.19e-02 6.88e-04 4.69 7
hsa04070 Phosphatidylinositol signaling system 5.85e-02 1.39e-03 4.87 6
hsa04144 Endocytosis 6.14e-02 1.73e-03 2.81 11
hsa04270 Vascular smooth muscle contraction 6.14e-02 1.86e-03 3.96 7
hsa04725 Cholinergic synapse 6.14e-02 1.68e-03 4.03 7
hsa05410
Hypertrophic 
cardiomyopathy 
(HCM)
7.37e-02 2.38e-03 4.38 6
hsa05033 Nicotine addiction 7.58e-02 2.77e-03 6.74 4
hsa00604 Glycosphingolipid biosynthesis 7.58e-02 2.78e-03 10.37 3
hsa05214 Glioma 7.65e-02 2.97e-03 5.05 5
hsa04540 Gap junction 9.38e-02 3.85e-03 3.98 6
hsa04010 MAPK signaling pathway 9.38e-02 4.66e-03 2.48 11
hsa04721 Synaptic vesicle cycle 9.38e-02 4.63e-03 4.56 5
hsa04720 Long-term potentiation 9.38e-02 4.10e-03 4.69 5
hsa04728 Dopaminergic synapse 9.38e-02 4.53e-03 3.38 7
( Continued)
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Figure 5: Percent distribution of edited (in green) vs non edited (in purple) variants of miR-376c-3p in 7 C/P pairs of 
ST samples, 3 C/P pairs of LT samples, and in one healthy white matter sample (SB).
two sample test for equality of proportion with continuity 
correction gave a p-value = 3.6 × 10−12 (X-squared 
of 48.3). Interestingly, we also noticed that LTC samples 
display, on average, a fraction of edited variants higher 
than the STC samples. For these two groups too, we 
obtained a p-value = 2.2 × 10−16 (X-squared of 245.4).
To understand if the editing of miR-376c-3p might 
affect its mRNA target cohort, we performed a target 
prediction analysis of the two forms, edited vs unedited, 
and then submitted the two lists of predicted mRNAs to a 
functional annotation clustering analysis. We thus found 
that the edited forms are predicted to target mRNAs 
grouping in clusters such as “Hedgehog signaling 
pathway” and “Wnt signaling pathway” (Suppl. Table 2a), 
typically characterizing tumors and GBM in particular. 
On the contrary, unedited miR-376c-3p predicted targets 
hsa05412
Arrhythmogenic 
right ventricular 
cardiomyopathy 
(ARVC)
9.65e-02 5.21e-03 4.44 5
hsa05031 Amphetamine addiction 9.65e-02 5.21e-03 4.44 5
hsa04260 Cardiac muscle contraction 1.04e-01 5.83e-03 4.32 5
hsa04062 Chemokine signaling pathway 1.63e-01 9.48e-03 2.70 8
B
Id category Name category Adjusted p value
Non corr 
p value Fold enrichment # Genes
The grey background highlights KEGG categories with an adjusted p-value < 0.05. Adjusted p-value represents the Benjamini – 
corrected p-value
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(Suppl. Table 2a) are enriched in mRNAs coding for proteins 
involved in sugar transmembrane transport and in apoptosis, 
completely absent among those predicted to be targets of 
edited miR-376c-3p. Of note, among the predicted targets 
of unedited miR-376c-3p, overexpressed in C samples, we 
found key cell control genes, such as CDKN1A (coding for 
p21) or the microRNA processing enzyme Drosha.
All these data indicate that a certain loss of the 
physiological A to G editing of miR-376c-3p occurs in 
GBM samples compared to healthy tissues and also to the 
peripheral areas, and that this likely induces a shift in the 
mRNAs targeted by miR-376c-3p, in turn driving GBM 
cells towards cell proliferation and other typically tumoral 
functions.
DISCUSSION
We undertook a multifaceted molecular analysis 
of a group of tissue samples from glioblastoma patients, 
and specifically focused on two main issues: i) RNAs 
whose expression is perturbed not only in glioblastoma 
tumor samples (Cs), but also in the peritumoral areas (Ps), 
compared to white matter healthy controls; ii) molecules 
distinguishing the tissues from “long term” (LT) GBM 
patients (that survived longer than 36 months after 
diagnosis) from those from the most common “short term” 
(ST) ones. The rationale behind these two main goals 
of our work is the idea that the different survival of LT 
compared to ST patients might be explained by different 
molecular signatures, to which a significant contribute 
may be provided by the peritumoral areas, including 
multiple cell types. More generally, our view, supported 
by the data we are presenting, is that peritumoral areas are 
actively involved in glioblastoma even when a clear tumor 
phenotype is not detectable.
A mesenchymal signature, indicative of 
a possible infiltration of stromal cells, 
characterizes C and P samples compared to 
healthy white matter and specifically short-term 
tumors
The analysis of modulated RNAs affecting both 
tumor centers and peritumoral areas unveiled the 
Table 6a: List of microRNAs overexpressed in C and P samples vs healthy white matter (HC). 
miRNA HC LTC LTP STC STP
hsa-miR-106b-5p 119 537 1025 2887 1222
hsa-miR-10b-5p 11 557 1445 1589 311
hsa-miR-1248 18 255 128 174 101
hsa-miR-1260a 151 1033 906 933 431
hsa-miR-1260b 14 101 128 66 82
hsa-miR-148a-3p 89 529 266 588 300
hsa-miR-16-2-3p 15 51 72 156 50
hsa-miR-182-5p 11 75 52 1322 230
hsa-miR-183-5p 2 51 15 508 87
hsa-miR-18a-5p 35 135 441 460 329
hsa-miR-210-3p 3 214 212 355 199
hsa-miR-21-3p 0 37 37 68 10
hsa-miR-21-5p 1132 15222 40876 51388 7627
hsa-miR-24-2-5p 6 59 76 70 36
hsa-miR-3065-5p 7 134 47 36 32
hsa-miR-454-3p 33 208 173 344 319
hsa-miR-503-5p 5 23 22 74 17
hsa-miR-92b-5p 2 33 108 74 18
hsa-miR-93-5p 1439 6443 7835 12378 6080
The numbers shown represent the cpm median values for each class of samples. Only miRNAs with a module fold change (log2) higher 
than 1.5 in all four comparisons (LTC vs HS, LTP vs HS, STC vs HS, STP vs HS) and with at least 50 cpm in one of the 5 samples 
are reported
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overexpression of several molecules belonging to the 
“mesenchymal signature” of glioblastoma [54, 13, 
10], that greatly overlaps with the infiltration of tumor-
supporting “stromal cells”, a role that in brain is played by 
reactive astrocytes and microglia.
Among these RNAs, in our view the most notable 
ones are CXCL14 and TGFBI. We find CXCL14 
overexpressed in C and P samples (both ST and LT) vs 
healthy white matter; however, while its expression levels 
are comparable in LTCs and in LTPs, it is overexpressed 
in the majority (7/9) of STC vs STP samples. Indeed, we 
confirmed CXCL14 expression by IHC (Suppl. Fig. 4) in 
the cytosol and extracellular region of reactive astrocytes 
in STC samples, whereas STP samples showed a lighter 
staining in the cytoplasm of some astrocytes, likely 
representing the activated ones. A few works have 
been published using only murine models, showing 
that CXCL14 is expressed by activated microglia after 
induction by GBM conditioned medium [24]; our finding 
of CXCL14 increased expression in STCs compared to 
STPs may reflect a higher level of microglial or more 
probably reactive astrocyte infiltration in ST tumor centers 
compared to peritumor areas, which, on the contrary, 
doesn’t characterize LT tumor centers when compared 
to their own peritumor areas. This hypothesis could be 
supported by our data collected in the comparison of 
STCs vs STPs: among the RNAs overexpressed in STCs 
vs STPs, COL1A1, COL1A2 and COL5A1 are known 
markers of the mesenchymal glioblastoma subtype, as 
well as IGFBP6, DCBLD2 and OLFM1, all expressed by 
microglia or reactive astrocytes [13, 10]. Notably, such an 
enrichment in genes expressed by stromal cells is absent 
among RNAs overexpressed in LTCs vs LTPs.
Another relevant example is TGFBI which, besides 
its recognized role as a marker of the mesenchymal class 
of glioblastoma [13], was described, in conjunction with 
SOX4, as a mediator of non-SMAD mediated TGF-beta 
signaling pathways in glioblastoma [55]. TGFBI is mainly 
secreted in the extracellular matrix, where it interacts 
with several other components, such as collagens, among 
which collagen IV alpha 2, whose mRNA is among those 
overexpressed in all C and P samples of our study. Our data 
thus not only confirm those reported by Lin and coworkers 
[55], but extend the significance of TGFBI overexpression 
also to peritumoral regions. Notably, when we searched 
for TGFBI protein expression by IHC, we found it in the 
extracellular space and in the basement membrane of 
vessels of C tissues, while it marked less intensely single 
cells in P samples (Suppl. Fig. 4), with a difference of 
expression reflecting that observed for TGFBI mRNA 
by SAGE. In P regions showing clear evidence of tumor 
cell infiltration, TGFBI staining was found extracellularly 
and in the basement membrane of vessels, reflecting the 
staining observed in C samples (not shown). Specific 
studies addressing the question of which cell types produce 
and secrete TGFBI in GBM microenvironment are surely 
needed, in order to understand its possible paracrine or 
autocrine roles in this context.
In general, we observed that, among overexpressed 
mRNAs shared throughout all C and P samples, the level 
Table 6b: KEGG pathways enriched for mRNAs predicted to be targeted by miRNAs listed 
in Table 6a. 
KEGG PATHWAY P value # genes # miRNAs
Neurotrophin signaling pathway 5.91e-19 54 18
Regulation of actin cytoskeleton 1.82e-18 84 16
PI3K-Akt signaling pathway 1.82e-18 118 17
Axon guidance 2.78e-17 57 16
TGF-beta signaling pathway 2.76e-15 37 16
ErbB signaling pathway 8.16e-13 40 15
Endocytosis 1.08e-11 71 17
Ubiquitin mediated proteolysis 7.57e-12 53 16
Focal adhesion 1.44e-11 71 16
Pathways in cancer 3.91e-11 114 18
p53 signaling pathway 6.66e-11 30 14
MAPK signaling pathway 6.66e-11 87 17
Wnt signaling pathway 1.02e-10 58 18
The number of genes targeted in each pathway and the number of miRNAs predicted to target those mRNAs are indicated in the third and 
fourth column, respectively
Oncotarget22544www.impactjournals.com/oncotarget
Table 6c: List of microRNAs underexpressed in C and P samples vs healthy white matter (HC). 
miRNA HC LTC LTP STC STP
hsa-miR-1185-5p 59 16 8 10 10
hsa-miR-1224-3p 245 29 7 4 25
hsa-miR-124-5p 359 83 13 36 26
hsa-miR-1249 1468 153 199 64 275
hsa-miR-127-5p 104 23 7 23 11
hsa-miR-128-3p 28670 4382 2616 3413 6134
hsa-miR-129-1-3p 343 55 16 16 61
hsa-miR-129-2-3p 6142 1786 321 292 695
hsa-miR-129-5p 494 126 60 29 94
hsa-miR-137 446 98 18 41 100
hsa-miR-139-3p 74 20 0 0 6
hsa-miR-139-5p 20625 3441 1018 547 2306
hsa-miR-154-3p 216 43 35 63 71
hsa-miR-3200-3p 416 19 5 0 14
hsa-miR-323a-3p 2795 610 246 289 389
hsa-miR-323b-3p 330 68 24 34 63
hsa-miR-326 1204 423 216 103 183
hsa-miR-329-3p 1241 255 53 125 236
hsa-miR-369-3p 142 38 15 47 30
hsa-miR-376a-5p 100 32 6 19 16
hsa-miR-381-5p 89 27 3 8 11
hsa-miR-431-3p 81 16 0 3 4
hsa-miR-485-3p 387 90 16 41 38
hsa-miR-487a-3p 226 57 29 51 55
hsa-miR-487b-3p 5864 1661 414 412 773
hsa-miR-491-5p 166 54 8 4 12
hsa-miR-504-5p 460 107 58 9 16
hsa-miR-582-5p 331 46 54 85 75
hsa-miR-628-5p 504 163 152 44 132
hsa-miR-6511b-3p 190 50 46 25 47
hsa-miR-656-3p 123 23 11 14 26
hsa-miR-668-3p 57 12 3 4 5
hsa-miR-7-1-3p 521 150 148 146 179
hsa-miR-7-2-3p 143 19 10 12 22
hsa-miR-769-3p 271 42 26 23 27
( Continued)
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of modulation (Log2FC, see Table 2b) vs healthy white 
matter was frequently comparable in LTCs and LTPs, while 
it was almost always higher in STCs compared to STPs. 
We propose that this may be explained by an enhanced 
transformation stage characterizing STCs, but at the same 
time may imply that several molecular pathways supporting 
tumor growth are already “switched on” in peritumor areas.
An “oncomir” expression pattern distinctive 
of TGFβ activation characterizes all C and P 
samples compared to healthy white matter
Also when we analyzed the microRNAs extensively 
overexpressed throughout all C and P samples compared 
to healthy white matter, we found many that may represent 
both signs of TGFβ active pathways and mediators of a 
general state of immune escape typically sustaining glioma 
growth. In fact, among the several known “oncomiRs” 
overexpressed in our samples, we found miR-106b and 
miR-93, recently shown to target NKG2DL, a ligand 
of the activating receptor of natural killer (NK) cells 
NKG2D, and thus suggested to contribute to the immune 
evasion typical of glioblastoma cells [56]. Mir-183, that 
we found to characterize most of our samples and also to 
distinguish the infiltrated vs the non-infiltrated peritumoral 
areas, is a TGFβ-induced miRNA previously reported 
to suppress tumor-associated natural killer cells, thus 
explaining one of the ways through which TGFβ plays its 
immunosuppressive roles in tumor microenvironment [57]. 
We can recognize several further microRNAs positively 
correlated with TGFβ role as a supporter of tumor growth: 
miR-21, shown to be induced by TGFβ1 and to target 
SMAD7, thus leading to the TGFβ-promoted formation 
of cancer associated fibroblasts [58]. Mir-106 too was 
described as deeply involved in TGFβ protumorigenic 
signaling through targeting of SMAD7, in turn inducing 
EMT in breast cancer [59], similarly to miR-10b, induced 
by TGFβ1 and promoting EMT in breast cancer [60]. 
Specifically in glioblastoma, miR-182 is induced by 
TGF-β, leading to prolonged NF-κB activation in a glioma 
subset [48]. Even among the underexpressed miRNAs 
we found possible indications of TGFβ action, such as 
Table 6d: KEGG pathways enriched for mRNAs predicted to be targeted by miRNAs listed 
in Table 6c. 
KEGG PATHWAY P value # genes # miRNAs
MAPK signaling pathway 1.37e-41 135 34
PI3K-Akt signaling pathway 1.43e-40 168 33
Focal adhesion 3.05e-31 104 31
Wnt signaling pathway 5.92e-29 89 28
Axon guidance 6.27e-27 78 33
Pathways in cancer 4.06e-25 170 34
Dopaminergic synapse 6.08e-25 78 35
Ubiquitin mediated proteolysis 8.91e-24 77 31
Neurotrophin signaling pathway 2.71e-22 72 32
Glioma 5.01e-20 44 25
ErbB signaling pathway 1.61e-18 57 31
TGF-beta signaling pathway 1.94e-18 51 27
miRNA HC LTC LTP STC STP
hsa-miR-769-5p 355 60 19 79 104
hsa-miR-770-5p 190 55 4 8 12
hsa-miR-874-3p 3834 1002 590 470 748
hsa-miR-99b-5p 1186 71 217 121 171
The numbers shown represent the cpm median values for each class of samples. Only miRNAs with a module fold change (log2) higher 
than 1.5 in all four comparisons (LTC vs HS, LTP vs HS, STC vs HS, STP vs HS) and with at least 50 cpm in one of the 5 samples 
are reported
The number of genes targeted in each pathway and the number of miRNAs predicted to target those mRNAs are indicated in the third and 
fourth column, respectively. The significance level is indicated by a corrected p-value
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the reduced expression of miR-127, demonstrated to be 
under the negative control of TGFβ in hepatocellular 
carcinoma [61]. To our knowledge, ours is the first work 
where a systematic measurement of microRNA expression 
is performed in glioblastoma peritumoral areas, and the 
results yielded by such a study, together with the gene 
expression analysis of the same samples, indicate that 
peritumoral regions share with frankly tumor areas a 
mRNA and microRNA signature distinctive of TGFβ 
activation and possibly of the involvement of cell types 
mediating a general immunosuppressive condition.
ST tumor and peritumor areas, compared to 
LT ones, show an enrichment of mRNAs known 
to be expressed by activated astrocytes and 
microglia
When we compared tumor centers to peritumoral 
areas, in the ST group we observed several signs of 
a higher participation of reactive cell types, such as 
microglia and reactive astrocytes, that could be depicted 
also as a generally more “mesenchymal” feature compared 
to what we found in LTs. Suggestive of a such a view, 
in the STC vs STP comparison, but not in the LTC-LTP 
one, we found the overexpression of prolylendopeptidase, 
a serine protease digesting ECM and typically expressed 
by microglia [62], and that of ARHGAP29, expressed by 
reactive astrocytes and microglia [10]. An even stronger 
indication was provided by the direct comparison of 
STCs vs LTCs, that underscored a clear enrichment of 
RNAs known to be expressed by activated astrocytes 
and microglia, such as carbonic anhydrase III (CA3), 
CD44 and TGFBI. In particular, CD44 is the receptor 
for hyaluronate and osteopontin [63, 64], critical for cell 
adhesion and invasion, and is a key marker of reactive 
astrocytes, whose infiltration in the tumor and in the 
peritumoral area correlates with a worse prognosis [11]. 
It has also been recently shown that CD44 expression, 
being a marker of TNFalpha/NFkB-induced mesenchymal 
differentiation of glioblastoma, correlates with poor 
radiation response and shorter survival [54]. Our IHC 
results show CD44 localized at the membranes of specific 
cells, most likely reactive astrocytes, in C samples, 
and throughout the intricate net of cell processes in 
P tissues (Suppl. Fig. 4). A gene that resulted strongly 
underexpressed in our STC samples vs the LTC ones 
was BCAR3, whose role in glioblastoma has never been 
revealed before. However, it has very recently reported 
that it is downregulated by TGFβ and it can also inhibit 
TGFβ/SMAD signaling in breast cancer, where its 
expression associates with favorable disease outcome [65]. 
Our finding of its reduced expression in STCs vs LTCs is 
intriguing as it suggests that in glioblastoma too it may 
play a role similar to that performed in breast cancer, in 
the context of TGFβ-modulated pathways. Notably, also 
in the comparison of the ST peritumoral areas as opposed 
to the LT ones, we found some indications of a possible 
higher contribution of tumor “stromal” cells, as reactive 
astrocytes. IGFBP5 mRNA in fact, overexpressed in STPs 
vs LTPs, even if not previously described in the context 
of GBM, had been reported as expressed by reactive 
astrocytes supporting retinoblastoma growth [36]. By IHC, 
we were able to detect for the first time IGFBP5 in the 
cytoplasm and extracellular matrix of reactive astrocytes 
in C tissues from short term patients, and also in the 
cytoplasm of astrocytes present in STP samples, though 
with a lower intensity (Suppl. Fig. 4), while we did not 
find it in LT peritumoral regions (not shown). In addition, 
we found a sound overexpression of the extracellular 
protein lumican in LTPs as compared to ST ones, still 
corroborating the view of a great involvement of tumor 
microenvironment in the definition of long-term vs short-
term survivors. This stromal protein has been very recently 
shown to positively correlate with prolonged survival after 
tumor resection in in pancreatic ductal adenocarcinomas, 
due to its limiting role in EGFR-expressing pancreatic 
cancer progression [66].
A reduced A to G editing of miR-376c-3p 
distinguishes tumor centers from peritumor 
areas and is more evident in STCs compared 
to LTCs
When we considered the results of microRNA 
expression profiling, we were not able to find miRNAs 
clearly distinguishing STCs from LTCs in a statistically 
significant way (i.e. FDR < 0.05). However, we found a 
significant difference in the percentage of the A to G edited 
variants of miR-376c-3p: LTCs harbored, on average, 
more edited mir-376c-3p than STCs. In addition, we also 
found that this same miRNA is more edited in all Ps vs 
Cs. The A to G editing of miR-376c-3p had previously 
been described, specifically in brain, where adenosine 
deaminase acting on RNA-1, ADAR1, was shown to 
be the enzyme responsible of this specific editing [67]. 
Intriguingly, our SAGE data revealed a reduced expression 
of a brain-specific member of the adenosine deaminase 
gene family, ADARB2, in all Cs and Ps, of both ST and 
LT patients. Even if the editing activity of this enzyme has 
never been formally demonstrated, and an inhibitory role 
was rather proposed for ADARB2 [68], the concomitant 
reduction of miR-376c-3p editing and ADARB2 
expression suggest a functional correlation between 
these two findings. A reduced editing of miR-376a, 
another member of the same miRNA cluster located on 
chromosome 14, and evolutionarily related to miR-376c, 
was previously reported in glioblastoma compared to 
healthy control tissues [69], and a functional consequence 
of this was identified in the differential targeting of 
specific mRNAs by the edited vs the non-edited miR-376a 
isoforms. In our case, we did not find any difference in the 
levels of miR-376a editing when comparing Cs vs Ps, or 
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all samples vs healthy controls. However, the indication, 
obtained by target prediction, that some mRNAs highly 
relevant for tumor cell biology (e.g. CDKN1A and 
Drosha) could be differentially targeted by the non-edited, 
tumor enriched miR-376c isoform, is surely intriguing and 
deserves further investigation.
In conclusion, this comprehensive study of GBM 
tissues and peritumoral areas indicates some key molecules 
characterizing LT from ST tissues, and at the same time 
shows the commonality of some molecules and pathways 
(e.g. TGFβ) between tumor centers and peritumoral areas, 
strongly suggesting that such molecules/pathways should 
be targeted in both areas in order to fight, and defeat, 
glioblastoma.
MATERIALS AND METHODS
Tissue procurement and RNA extraction
In this study we used tissue samples coming from 
13 GBM patients; 9 patients were classified as short- term 
survival and 4 cases as long-term survival (survival ≥ 36) 
(Table 1). All patients provided informed consent to use 
their tumor and peritumor material as well as clinical 
data for research purposes, none of them was identifiable. 
The study was approved by the local ethics committee 
(Catholic University Ethics Committee, Rome).
Tumor removal was achieved with resection 
margins that included the neighboring, apparently normal 
tissue (between 1 cm and 2 cm from the tumor border; 
larger resections were performed in tumors that grew far 
from eloquent areas) and the tumor, which were removed 
entirely en bloc.
Neuronavigation and intraoperative ultrasounds 
were used to maximize the extent of intracranial tumor 
resection. Thirty-five days after surgery (range, 30–40 
days), patients received an external source limited-
field radiotherapy (with an average dose of 60 grays 
administered in fractions). Simultaneously, chemotherapy 
with temozolomide (Temodal) was administered at a dose 
of 75 mg/m2 per day. After a 1-month break, patients 
received up to 6 cycles of temozolomide at a dose from 
150 to 200 mg/m2 per day on the standard schedule of 
5 days per week every 28 days. All patients underwent the 
same adjuvant therapy protocol.
All patients were followed as outpatients 1 month 
after surgery and every 3 months thereafter.
We obtained 13 pair samples from different areas: 
Tumor and Peritumor white matter tissues close to the 
tumor, between 1 cm and 2 cm from the tumor border. 
One series (tumor and peritumor tissues) was immediately 
fixed in 10% neutral buffered formalin for histological 
analysis and the second one was immediately frozen on 
dry ice for molecular analysis. All histological samples 
were reviewed by a board-certified neuropathologist and all 
tumors were classified as glioblastoma (WHO IV). Multiple 
levels of each paraffin block of samples used for research 
purposes (tumor and peritumor) were thoroughly examined. 
Specimens were histologically assessed using H&E sections. 
Neoplastic cells were identified by their nuclear atypia 
and heteropyknotic staining. Glial fibrillary acidic protein 
(GFAP) immunolabeling of peritumor area samples was 
used routinely to identify reactive astrocytes, which were 
identified by their clear, large eccentric nuclei; eosinophilic 
cytoplasm; and long, thick, stellate, GFAP-positive 
processes, according to Hoelzinger et al. [70].
Specimens from surrounding tumor area were 
assessed histologically by 2 independent pathologists who 
identified the presence of neoplastic cells in each sample. 
Two sections from each area were examined by 2 different 
observers independently, and at least 1000 to 2500 cells 
from 4 to 10 randomly selected fields in each section 
were counted. By using a light microscope (Axioskop 
2 plus; Zeiss), the presence of tumor cells was evaluated at 
3400X magnification. Samples with discrepant scoring were 
re-evaluated jointly on a second occasion, and agreement 
was reached. The results were categorized as ‘infiltrated’ 
if tumor cells were detected in at least 1 specimen. In the 
peritumoral areas classified as “non-infiltrated” in this study, 
no tumor cells were seen, and the expression of Ki-67, 
marker of proliferation detected by immunohistochemistry, 
was less than 1%. On the contrary, the peritumoral areas 
classified as “infiltrated”, showed a Ki-67 immunoreactivity 
of >> 1%.
CTRL specimens were derived from patients at the 
same ages operated for deep cavernomas with radiological 
signs of recent bleeding.
Total RNA was isolated from all tissue samples 
by RNA/DNA/Protein Purification Kit (Norgen, CA) as 
described by manufacturer’s instructions followed by 
clean-up DNase digestion on column by RNase-Free 
DNase Kit (Norgen, CA).
Western blot analysis
For Western blot analysis, total protein extract 
was isolated from tissue samples by RNA/DNA/Protein 
Purification Kit (Norgen, CA) as described by manufacturer’s 
instructions. Equivalent amounts of protein extract were 
separated by electrophoresis on 12% SDS-PAGE gels and 
blotted onto nitrocellulose. The membranes were blocked 
with 5% nonfat dry milk and 0.1% Tween-20 in Phosphate-
buffered saline and then incubated with antibodies followed 
by appropriate horseradish peroxidase-conjugated secondary 
antibody (Promega, USA). Rabbit polyclonal anti-LMTK3 
(Abcam, UK) was used diluted 1:500, rabbit polyclonal 
anti-TGFBI (Thermo Scientific, USA) was diluted 1:1000, 
rabbit polyclonal anti-SOCS2 (Thermo Scientific, USA) was 
diluted 1:200. Rabbit polyclonal anti-β-actin (Sigma, USA) 
diluted 1:400 was used to reveal β-actin as a loading control.
SAGE sequencing and analysis
SAGE barcoded libraries were prepared from 27 total 
RNA samples extracted independently from the cores and 
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peritumoral regions of 13 glioblastoma tumors and 1 sample 
of healthy white matter. Each library was generated by using 
the SOLiD™ SAGE™ Kit with Barcoding Adaptor Module 
and a SOLiD™ RNA Barcoding Kit (Catalog nos. 4452811 
and 4427046, Applied Biosystems, Foster City, CA), 
following the manufacturer’s instructions. The barcoded 
libraries were combined and sequenced on 3 full slides on 
an Applied Biosystems SOLiD 4 System. Sequencing length 
was 35 bp. Library preparation, barcode addition, emulsion 
PCR, and SOLiD sequencing were performed at Genomnia 
Srl (Lainate, Milan, Italy).
Suppl. Table 3a summarizes all the samples and 
the target mapping percentages associated with this 
experiment. All the SAGE Color Space sequence files 
generated by the sequencing were corrected de novo 
for sequencing errors before mapping on the reference 
transcriptome, using the Life Technologies SAET (SOLiD 
Accuracy Enhancer Tool) version 2.2 program (https://
www.biostars.org/static/downloads/solid/solid-denovo-
assembly/saet.2.2/SAET.v2.2.pdf).
The error-corrected sequences were then trimmed to 
27 nt from the original 35. These were mapped using the 
bowtie version 0.1.27 version 2 software against a reference 
3′ UTR database derived from RefSeq and relative to 
the hg19 version of the human genome sequence. The 
alignments were parsed with ad-hoc created Perl scripts 
in order to extract and count the aligned SAGE tags 
beginning with the CATG sequence, with max 1 mismatch 
(globally) with the reference sequence and with a single 
mapping position on the reference sequence. The aligned 
reads counts have been then grouped by target RefSeq ID; 
analyzed for differential expression with the Bioconductor 
EdgeR library; annotated with a proprietary script.
The results consist in tables reporting the differentially 
expressed genes (by P value and False Discovery rate) for 
each of the comparisons which are summarized below.
STP vs STC; LTP vs LTC; LTP vs STP; LTC vs 
STC; STPs vs healthy control; LTPs vs healthy control; 
STCs vs healthy control; LTCs vs healthy control.
Single Sample Gene Set Enrichmemnt Analysis 
was performed using the SGEA module from the Gene 
Pattern Public Server (http://www.broadinstitute.org/
cancer/software/genepattern) and the classified gene lists 
associated with the subtype calls from the expression 
values of the core TCGA samples (https://tcga-data.nci.
nih.gov/docs/publications/gbm_exp/TCGA_unified_
CORE_ClaNC840.txt).
Feature selection with ReliefF
Weka 3.7 [71] was used to employ the the ReliefF 
algorithm [14]. ReliefF computes merit as the difference 
between the probability of observing a different value 
of a metric in a different class and the probability of 
observing a different value of a metric in the same class. 
Merit therefore simultaneously emphasized inter-class 
dishomogeneity and intra-class homogeneity (i.e. merit 
is high when an RNA is both different between different 
classes and equal between equal classes or in within 
the same class). The RNA molecules were then ranked 
according to merit, and the first 50 highest ranking 
molecules were selected for visual representation through 
a heatmap depicting the ratio of expression between 
classes for each RNA molecule. Mathematica 9 (R) was 
employed to generate the heatmaps.
MicroRNA sequencing and analysis
A second aliquot of the same total RNA samples 
analyzed by SAGE sequencing was used to explore the 
small RNA fraction, after enrichment using the Invitrogen 
PureLink®miRNA Isolation Kit. The amount and quality of 
the enriched small RNA was examined using the Agilent 
Bioanalyzer. Barcoded sequencing libraries were generated 
from an average of 10 ng of purified small RNA using 
the Applied Biosystems SOLiD™ Small RNA library 
protocol (July 2011 Rev.B) with the Total RNA-Seq Kit 
(PN 4445374). The libraries were pooled and sequenced 
with the SOLiD 5500XL platform using 9 lanes. Sequence 
files in Colorspace format (.csfasta and .qual) included in 
the .xsq file were mapped and analysed using the ‘small 
RNA’ Lifetech Lifescope version 2.5.1 pipeline, using as 
targets the human genome GRCh37/hg19 and the dataset 
of mature sequences and precursors mirBase version 20 
(June 2013). Matches with the genome repetitive elements 
(SINE, LINE..), snoRNAs, piRNAs, tRNAs and rRNAs 
were eliminated by the results through preliminary filtering. 
Sequence data are shown in Suppl. Table 3b. Filtered small 
RNA alignments in .bam format were converted in .fastq 
format and subjected to further analyses.
Read mapping and isomiRNA counts were made by 
using a stand-alone Perl program able to detect miRNA 
variants (isomiRNAs) in small RNA-Seq experiment 
[Grassi et. al. in preparation]. The program compares 
the sequenced reads with respect to canonical mature 
miRNA and relative premiRNA present in miRBase 
(version 20) [72]. For each expressed isomiRNA, the 
occurrences were counted and possibly grouped in order 
to define the corresponding miRNA counts. Subsequently, 
miRNA counts were normalized by using the TMM 
normalization procedure [73]. The samples were classified 
in two groups based on miRNA expression, according 
to the method described by Brunet et al. [74], by using 
the non-negative matrix factorization (NMF) R package 
[75]. In 10 patients, miRNA expression of C samples 
was compared with respect to that of the corresponding 
P samples. The differential expression analysis was made 
by using a generalized linear model (GLM) implemented 
in edgeR and able to handle the paired experimental 
design [76]. We considered for the analysis only the 
miRNAs with counts per million (cpm) > =10 in more than 
4 (at least in one sample in the pair) of the 10 analyzed 
C-P pairs (469 in total). The derived p-values and the 
corresponding FDR values are reported in Suppl. Table 4. 
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The comparison between the infiltrated P samples 
(7 samples) with non infiltrated P samples (3 samples) was 
made by using edgeR in the standard modality. Due to the 
reduced number of samples, we limited the analysis to the 
464 miRNAs with at least 10 cpm in at least 3 samples.
Target genes of miR-376c-3p and its 6n AtoG edited 
variant were predicted by intersecting the results of the 
two programs miRanda [77] and PITA [78]; in both cases 
all the 3′UTRs of the Genecode genes derived by UCSC 
have been analyzed.
Quantitative real-time-PCR
qRT-PCRs were performed to validate the 
expression of specific mature miRNAs, using pre-
designed stem-loop primers (TaqMan MicroRNA Assay, 
Applied Biosystems-Life Technologies). 10 ng of total 
RNA isolated from tissue samples was used to generate 
cDNA by TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems-Life Technologies) according to the 
manufacturer’s instructions.
For mRNA, 0.5 μg of total RNA isolated from tissue 
samples (pre-treated with DNase I) was used to generate 
cDNA by the SensiFAST cDNA Synthesis Kit (Bioline, 
London, UK) according to the manufacturer’s instructions.
qRT-PCRs were conducted on an StepOnePlus Real-
Time PCR System (Applied Biosystems-Life Technologies) 
using TaqMan Universal PCR Master Mix and the specific 
TaqMan® Assays (probe and primer sets) (Applied 
Biosystems-Life Technologies). The small endogenous 
nuclear RNA U6 (RNU6B) and TBP were used as controls 
for normalization of mature miRNAs and mRNAs, 
respectively. The relative amount of each substrate was 
calculated by the 2−ΔΔCT method [79]. All the primers were 
supplied by Applied Biosystems: CA3, ID Hs00193123_
m1; BCAR3, ID Hs00981962_m1; ENPP2, 
ID Hs00905117_m1; CXCL14, ID Hs01557413_m1; 
TOP2, ID Hs01032137_m1; COL1A2, ID Hs00164099_m1; 
MSR1, ID Hs00234007_m1; ADARB2, ID Hs00218878_
m1; LPHN2, ID Hs00202347_m1; NES, ID 
Hs04187831_g1; H19, ID Hs00262142_g1; LINC00320, 
ID Hs01373561_m1; TBP, ID Hs99999910_m1; miR-
338-3p, ID 002252; miR-584-5p, ID 001624; miR-1290, 
ID 002863; RNU6B, ID 001093; miR-34c-5p, ID 000428; 
miR-23b, ID 000400; miR-590-5p, ID 001984; miR-219a-
5p, ID 00522; miR-340-5p, ID 002258.
Immunohistochemistry
Tissue samples were fixed in 4% formalin and 
embedded in paraffin. Two-μm thick serial sections were 
cut for each case; sections were mounted on poly-L-
lysine coated glass slides (X-tra® Adhesive slides, Leica 
Biosystems, Wetzlar, Germany) and dried overnight at 
37°C followed by 1 h at 60°C.
Briefly, sections were deparaffinized, hydrated 
and antigen was retrieved with Heat-Induced Epitope 
Retrieval (HIER) and pH 6 within the Dako PT Link 
instrument with a highly stabilized retrieval system (PT-
link, Dako, Glostrup, Denmark) except for GFAP that 
does not require retrieval. All immunohistochemical 
stainings were performed using UltraTek HRP Anti-
Polyvalent, developed with 3-3′diaminobenzidine, DAB 
Chromogen/Substrate Kit (ScyTek Laboratories, South 
600 West, Logan, USA) and counterstained with Harris’ 
Haematoxylin. In particular, endogenous peroxidase was 
blocked with Peroxide Block for 8 min, sections were 
incubated 20 min with Avidin/Biotin Blocking System 
(Spring Bioscience, Pleasanton, CA) and then with 
primary antibodies for 30 min at room temperature. In 
detail, CA3 [4A12-1A3], 1:200 dilution, and IGFBP5 
[MM0344-8D21] 1:50 dilution, (Novus Biologicals, 
Southpark Way, Littleton, CO, USA); CXCL14, 
1:50 dilution and TGFBI, 1:100 dilution, (Thermo Fisher 
Waltham, MA, USA); CD44, 1:100 dilution and GFAP, 
1:200 dilution, (Spring Bioscience, Pleasanton, CA); 
CD68 Monoclonal Mouse Anti-Human CD68, Clone 
PG-M1, 1:200 dilution, (Dako, Glostrup, Denmark), were 
used. Antibodies specific staining patterns were observed 
qualitatively. IHC evaluation was performed by a Leica 
BM5000 optical microscope, and Leica DMD108 digital 
microimaging sytem (Leica Microsystems; Wetzlar, 
Germany) was used to acquire images.
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